EW 124.76 Edwards Lifesciences Corp $EW Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
EW 124.76 Edwards Lifesciences Corp $EW Hit a 52 week high of 124.98 Currently at 124.76 +0.16 +0.13% With a day low of 124.61 and a total volume of 20,321.

EW Edwards Lifesciences Corp Recent Headline News

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 37 mins ago
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 32.96 (-0.03), ROKA: 3.64 (+0.06), EW: 125.05 (+0.45), ANGO: 16.99 (+0.03)

Global Prosthetic Heart Valves Industry
PR Newswire - Mon Nov 10, 5:55PM CST
This report analyzes the worldwide markets for Prosthetic Heart Valves in US$ Million by the following Product Segments: Mechanical valves, and Biological/Tissue valves. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 22 companies including many key and niche players such as -
EW: 125.05 (+0.45)

After Yesterday's Rally of 1.50% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 5:12PM CST
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $122.73 to a high of $124.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $123.68 on volume of 681,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 125.05 (+0.45)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 32.96 (-0.03), VOLC: 11.07 (+0.53), EW: 125.05 (+0.45), ANGO: 16.99 (+0.03)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 32.96 (-0.03), DXCM: 52.97 (-0.53), EW: 125.05 (+0.45), ANGO: 16.99 (+0.03)

Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Edwards Lifesciences Is Up 16.7% (EW)
Comtex SmarTrend(R) - Mon Nov 10, 8:09AM CST
Two weeks ago on October 23rd, 2014 Edwards Lifesciences (NYSE:EW) reported earnings and analysts, on average, expected earnings of $0.72 on sales of $546.0 million. Edwards Lifesciences actually reported earnings of $0.80 per share on sales of $607.4 million, beating EPS estimates by $0.08 and beating revenue estimates by $61.4 million. Shares of Edwards Lifesciences have climbed from $105.19 to $122.76, representing a gain of 16.7% since the company reported earnings 18 days ago.
EW: 125.05 (+0.45)

Edwards Lifesciences To Present At Credit Suisse 2014 Healthcare Conference
PR Newswire - Fri Nov 07, 12:59PM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix on Tuesday, November 11, 2014.
EW: 125.05 (+0.45)

Shares of EW Up 15.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:17AM CST
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on October 23rd, 2014 at $106.16. In approximately 2 weeks, Edwards Lifesciences has returned 15.30% as of today's recent price of $122.40.
EW: 125.05 (+0.45)

Downgrade Alert for Edwards Lifesciences (EW)
Comtex SmarTrend(R) - Fri Nov 07, 6:57AM CST
Edwards Lifesciences (NYSE:EW) was downgraded from Buy to Neutral at Sterne Agee today. The stock closed yesterday at $123.57 on volume of 784,000 shares, below average daily volume of 936,000. Edwards Lifesciences share prices have moved between a 52-week high of $123.68 and a 52-week low of $60.62 and closed yesterday at 104% above that low price at $123.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.8%.
EW: 125.05 (+0.45)

Insider Trading Alert - EW, SLAB And LCI Traded By Insiders
at The Street - Thu Oct 30, 10:45AM CDT
Stocks with insider trader activity include EW, SLAB and LCI
LCI: 51.59 (-0.22), SLAB: 45.47 (unch), EW: 125.05 (+0.45)

Look for Shares of Edwards Lifesciences to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Wed Oct 29, 4:26PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $118.01 to a high of $120.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $118.84 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 125.05 (+0.45)

Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 108.59 (+1.57), PFE: 30.29 (+0.09), EW: 125.05 (+0.45), LLY: 68.52 (+0.17), ABBV: 64.00 (+0.21)

IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.45 (+0.03), EW: 125.05 (+0.45), IDXX: 150.97 (+3.79), ANGO: 16.99 (+0.03)

Morning Analysis on Health Care Equipment Stocks - Zimmer Holdings, Edwards Lifesciences, Varian Medical Systems, CareFusion, and Baxter Intl.
PR Newswire - Tue Oct 28, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Zimmer Holdings Inc. (NYSE: ZMH), Edwards Lifesciences Corporation (NYSE: EW), Varian Medical Systems Inc. (NYSE: VAR), CareFusion Corporation (NYSE: CFN), and Baxter International Inc. (NYSE: BAX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, October 27, 2014, the NASDAQ Composite ended at 4,485.93, up 0.05%, the Dow Jones Industrial Average edged 0.07% higher to finish the day at 16,817.94, and the S&P 500 closed at 1,961.63, down 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 755.35, up 0.12%, with the index also advancing 5.54% in the previous three months. Register for your complimentary reports on these five stocks at:
ZMH: 111.35 (+0.93), VAR: 87.22 (+1.90), BAX: 70.83 (+0.20), CFN: 57.52 (unch), EW: 125.05 (+0.45)

Can the Rally in Edwards Lifesciences (EW) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 6:48AM CDT
Can the Rally in Edwards Lifesciences (EW) Shares Continue?
EW: 125.05 (+0.45)

Critical Alerts For petroleo brasileiro, SodaStream, Edwards Lifesciences, Micron and Starbucks Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PBR, SODA, EW, MU and SBUX.
SBUX: 78.17 (+0.52), MU: 33.25 (+0.16), PBR: 10.40 (-0.22), EW: 125.05 (+0.45), SODA: 21.74 (-0.01)

Edwards Lifesciences (EW) Worth Watching: Stock Up 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:25AM CDT
Edwards Lifesciences (EW) was a big mover last session, with shares rising 11% on the day.
BABY: 34.28 (-0.20), PACB: 6.62 (-0.02), EW: 125.05 (+0.45), ANGO: 16.99 (+0.03)

SmarTrend Watching for Potential Pullback in Shares of Edwards Lifesciences After 11.00% Gain
Comtex SmarTrend(R) - Fri Oct 24, 3:53PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $113.22 to a high of $117.94. Yesterday, the shares gained 11.0%, which took the trading range above the 3-day high of $107.87 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 125.05 (+0.45)

Stocks Hold Near Session Highs; Drugmakers Shine Again
at Investor's Business Daily - Fri Oct 24, 1:50PM CDT
Stocks looked poised to end the week on a positive note Friday. The Dow Jones industrial average added 0.6%; the S&P 500 rose 0.5% and the Nasdaq picked up 0.4%. NYSE was tracking lower than Thursday's level. Nasdaq volume was tracking close to...
AMZN: 309.64 (+4.53), SYNA: 63.00 (+0.89), EW: 125.05 (+0.45), SLXP: 98.47 (+4.60), MTX: 76.77 (-0.08), CELG: 108.37 (+0.36), GILD: 108.59 (+1.57), JAZZ: 174.36 (-0.07), ALXN: 195.80 (unch), PG: 89.56 (+0.11), CTCT: 35.33 (-0.28)

Edwards Lifesciences Hits New High On Q3 Earnings
at Investor's Business Daily - Fri Oct 24, 11:29AM CDT
Medical device maker Edwards Lifesciences (EW) jumped 11% to an all-time high in the stock market today after it beat Q3 earnings estimates late Thursday and got a barrage of price-target increases from analysts. Edwards' earnings rose 14% over the...
MDT: 69.23 (+0.52), EW: 125.05 (+0.45)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Legal Scrutiny Over DarkNX Debacle

Updated Category News Views 70

Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...

Continue Reading
Minesto Teams Up to Unlock Tidal Power in Maldives

Updated Category News Views 154

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

Continue Reading
Bank of America Faces Legal Battle Over Compliance Failures

Updated Category News Views 39

Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...

Continue Reading
Veterans, Lawmakers Forge Paths in Spokane Forum

Updated Category News Views 0

Spokane Forum Sparks Action for Veterans' Policies Gonzaga University turned into a powerhouse of dialogue and determination as the Wounded Warrior Project (WWP) gathered over 145 veterans, elected officials, and advocate groups to hash out critical policy priorities. We're talking high-stakes discussions with real consequences, not just some feel-good meet-up. A...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 347

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Medline's Decade-Long WRAP Partnership: More Than Labels

Updated Category News Views 144

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Continue Reading
Reimagining Water: A Crisis and a Call to Action

Updated Category News Views 121

Time for a Change The head of the World Water Council, Loïc Fauchon, didn't mince words at the 9th Cairo Water Week. He proclaimed the old methods of water management are sinking under a flood of modern challenges. Toss in climate upheavals, ballooning cities, and unpredictable diets, and you've got yourself a swirling mess that traditional strategies just can’t mop...

Continue Reading
UFP Industries Fortifies Gulf Coast with $27M Buy

Updated Category News Views 65

UFP Industries Makes a Strategic Move Folks, it looks like UFP Industries (NASDAQ: UFPI) is making some solid moves down in the Gulf Coast, and they're shelling out $27 million to do it. This time, they've got their eyes on Apache Products, dba Acme Skid, a company that's been doing the heavy lifting in the pallet manufacturing space in Silsbee, Texas. Apparently, these...

Continue Reading
CSQR Faces Scrutiny Over Cash Flow Discrepancies

Updated Category News Views 40

Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...

Continue Reading
OncoHost's Research Links TKI Sensitivity to Biology

Updated Category News Views 121

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...

Continue Reading

Top 5 Most Recently Viewed Articles

Johnson & Johnson Stock Analysis: Performance and Predictions

Updated Category News Views 189

Current Performance of Johnson & Johnson Stock Johnson & Johnson (NYSE: JNJ) has made a significant impression this year, with the stock soaring nearly 42.9% to date. This impressive growth includes a rise of about 35% over the past six months and an 8.6% uptick in just the past month. Investors are keen to know what’s driving this positive trend. Recent Earnings Report...

Continue Reading
Thombar Empowers Specialty Crop Growers with New Banking Solutions

Updated Category News Views 141

Thombar Launches to Support Specialty Crop Growers A new banking platform is designed specifically for the unique needs of U.S. specialty crop growers. Introducing Thombar, a pioneering financial technology company that has just launched a new banking platform aimed at empowering specialty crop growers across the nation. Specializing in the diverse agricultural landscape,...

Continue Reading
Investigation of Snap Inc. Securities Fraud: What Investors Need to Know

Updated Category News Views 239

Understanding the Current Legal Situation for Snap Inc. The Gross Law Firm has issued an important notice that could impact numerous shareholders of Snap Inc. (NYSE: SNAP). As part of an ongoing class action lawsuit, those who purchased SNAP shares during the specified class period are encouraged to seek guidance on potential legal recourse. Who Should Consider...

Continue Reading
Alfa|SIGMA Achieves Impressive 1Q25 EBITDA Growth

Updated Category News Views 328

Alfa|SIGMA Reports Strong Results for 1Q25 Alfa, S.A.B. de C.V. has unveiled its financial accomplishments for the first quarter of 2025, showcasing a significant EBITDA of $220 million. This remarkable performance indicates the company's steady trajectory toward achieving its ambitious target of $1 billion for the full year. Highlights of 1Q25 Performance Transformative...

Continue Reading
Discover the A-688 Rotary Stage: Unmatched Precision in Motion

Updated Category News Views 149

Unveiling the A-688 Rotary Stage for Precise Motion Control The A-688 rotary stage, crafted by PI, represents an evolution in precision motion control solutions. This innovative product is designed to offer maintenance-free performance along with ultra-high resolution and high-speed capabilities. Frictionless Design for Superior Performance Engineered with a unique...

Continue Reading